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Abstract
Background: Pain in children and adolescents with cancer has been identified as an area where many healthcare
professionals seek guidance. This protocol details a systematic review whose aim is to explore current knowledge
regarding measurement instruments to assess pain (and pain-related distress) in children and adolescents with cancer.
After completion of the review, the information will be used in the development of a clinical practice guideline.
Methods: We will search four electronic databases (MEDLINE via PubMed, CINAHL, PsycINFO and HaPI). Additional
relevant studies will be identified by reference checking and expert consultation. All citations will be screened
independently by two reviewers in a three-step approach: first selection based on title, second selection based on
abstract, third selection based on full-text. Studies in children and adolescents with cancer that aimed to evaluate the
clinimetric properties of an existing pain measurement instrument or to develop a new pain measurement instrument
and that include at least one relevant outcome (reliability, validity, responsiveness, interpretability, clinical utility) are
eligible for inclusion. For all steps of evidence selection, a detailed list with eligibility criteria will be determined a priori.
Data extraction and quality assessment of included studies (according to the COnsensus-based Standards for the
selection of health Measurement INstruments, COSMIN criteria) will be conducted independently by two authors.
Discussion: This systematic review will provide an overview of the current literature regarding measurement
instruments to assess pain in children and adolescents with cancer. This knowledge synthesis will be used to formulate
recommendations for clinical practice. Also, by synthesizing existing evidence, knowledge gaps will be identified.
Systematic review registration: PROSPERO CRD42017072879
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Background
The survival outcome for children with cancer has im-
proved dramatically over the past 50 years [1]. In devel-
oped nations, the cure rates of childhood cancers now
exceed 80%, whereas, in the 1960s, cure rates in children
with cancer were the opposite: 20% [2, 3]. This remark-
able increase can be attributed to a multitude of factors
including the introduction of intensive treatment
protocols and highly coordinated modern multidisciplinary
care. However, these treatment modalities (mainly chemo-
therapy, radiotherapy, and surgery) also have clear undesir-
able side effects, both short- and long-term. Of these, pain
is among the most prevalent and distressing [4, 5].
Besides improving survival outcome, an important
focus in present day pediatric oncology is reducing mor-
bidity and improving quality of life during and after
treatment. This is referred to as supportive care, which
the Multinational Association of Supportive Care in
Cancer defined as “the prevention and management of
the adverse effects of cancer and its treatment across the
cancer continuum” [6]. As the field of supportive care is
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extremely broad, healthcare professionals often seek
guidance on how to optimally assess and manage the
undesirable effects of anti-cancer therapy [7]. To provide
this guidance, the project “Towards evidence-based
guidelines in childhood cancer” was initiated in 2014 [8].
As the first step in this project, we surveyed health care
providers to determine the topic areas in which they
wanted guidance. Pain assessment, evaluation (i.e., inter-
pretation of the assessment to evaluate treatment effect),
and management were identified as priorities [8, 9]. Re-
garding pain assessment, one of the great challenges in
pediatric oncology is selecting measurement instruments
that are age-appropriate, clinimetrically sound, and facili-
tate measurement of the various types of pain that chil-
dren and adolescents with cancer experience.
In previous research, the focus has been placed upon syn-
thesizing knowledge regarding pain measurement tools used
with other populations. A systematic review on pain inten-
sity assessment tools for adults concluded that numerical
rating scales are applicable for unidimensional assessment of
pain intensity in these patients [10]. Another recent system-
atic review focused on non-responsive adults and found that
there are multiple observational pain assessment tools avail-
able for this population [11]. However, there are clear differ-
ences between children and adults, and there are various
types of pain that children with cancer experience (e.g.,
neuropathic pain) that require specific guidance.
Thus, this systematic review will focus on assessment
and evaluation of pain and pain-related distress and is an
essential step in the development of a clinical practice
guideline regarding pain in children and adolescents with
cancer. For this guideline, the international guideline de-
velopment panel consists of 46 members (including
pediatric oncologists, nurses, anesthesiologists, pharma-
cologists, psychologists, and patient representatives) di-
vided into a core group (leads, coordinators, advisors) and
six working groups. Recommendations will be developed
for assessment and evaluation of pain, as well as for
pharmacological, physical, and psychological management
of tumor-, treatment-, and procedure-related pain.
The aim of this systematic review is to answer the ques-
tion: “Which are measurement instruments with strong
clinimetric properties to assess pain in children and ado-
lescents with cancer?” In line with the COnsensus-based
Standards for the selection of health status Measurement
INstruments (COSMIN) protocol for systematic reviews
of measurement properties, we defined the:
1) Construct of interest, i.e., pain (and pain-related
distress)
2) Population of interest, i.e., children and adolescents
with cancer
3) Type of measurement instrument, i.e., self-report
(using numbers or pictures/faces/colors), observer
ratings, behavioral measurement, and multidimen-
sional measurement
4) Measurement properties, i.e., reliability, validity,
responsiveness, interpretability, and clinical utility
Methods
The Preferred Reporting Items for Systematic Review
and Meta-Analysis Protocols (PRISMA-P) statement has
been followed in the development of this systematic re-
view protocol [12]. The completed PRISMA-P checklist
can be found in Additional file 1.
Eligibility criteria
To be included in this review, studies need to meet the
subjoined inclusion criteria. These are defined according
to the COSMIN criteria:
Construct of interest
Studies that evaluate instruments that aim to measure
the construct of pain (all types of pain). Distress is also
taken into account, when related to pain assessment.
Population of interest
Studies that encompass children and adolescents with
cancer, defined as (1) all participants < 25 years old or a
median ≤ 16 years old or a mean ≤ 16 years old and (2)
at least 75% of participants are diagnosed with cancer.
Type of measurement instrument
Studies that investigate a relevant measurement instru-
ment, which differs per clinical question and is either
self-reported (e.g., visual analog scale (VAS)) or a behav-
ioral pain/distress measurement instrument (e.g., the
COMFORT scale) [13, 14].
Measurement properties
At least one relevant outcome should be included. For
all clinical questions, relevant outcomes are reliability,
validity, responsiveness, interpretability, and clinical util-
ity (as defined by COSMIN, see Table 1).
Eligible study types
Only primary, quantitative studies will be included. The
sample size per study should be at least ten participants.
Studies should clearly state their aim is to evaluate the
clinimetric properties of an existing measurement in-
strument or to develop a new measurement instrument
(this criterion is in line with COSMIN) [15]. Studies
need to be published in a peer-reviewed medical journal,
with a full text available in the English language.
Literature searches
A search strategy has been developed in consultation
with an information specialist of Cochrane Childhood
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Cancer with extensive expertise in systematic reviews.
We will limit our results to publications in English, and
a publication date filter will not be imposed. The search
consists of four search strategies combined with the
‘AND’ Boolean operator, focusing on:
1. Children, with free text terms such as infan* and
child*, and MeSH headings such as pediatrics[mh]
2. Childhood cancer types, with free text terms such
as osteosarcom* and meningiom*, and MeSH
headings such as (leukemia, lymphocytic,
acute[mh])
3. Pain, with free text terms such as neuropath* and
ache, and MeSH headings such as pain[mh]
4. Measurement properties, with free text terms such
as validi* and test-retest*, and MeSH headings such
as psychometrics[mh] [16, 17]
The searches will be conducted in four electronic data-
bases, i.e., the Medical Literature Analysis and Retrieval
System Online (MEDLINE, via PubMed), the Cumula-
tive Index to Nursing and Allied Health Literature
(CINAHL), the Psychological Information Database
(PsycINFO), and the Health and Psychosocial Instru-
ments Database (HaPI). As an example, the full search
strategy that will be used in PubMed/MEDLINE can be
found in Table 2. For identification of additional studies
that were not included in this search, we will check all
references of included studies (backwards citation chas-
ing) and all studies that referenced the included studies
(forward citation chasing). Also, we will consult experts
for missing studies that meet the inclusion criteria. In
addition, to identify promising ongoing and recently
completed studies, we will hand search (1) conference
proceedings of the International Society on Pediatric
Oncology (SIOP) (2012 to 2017), the American Society
of Clinical Oncology (ASCO) (2012 to 2017), the Ameri-
can Academy of Pediatrics (AAP) (2012 to 2017), the
International Symposium on Pediatric Pain (ISPP) (2012
to 2017), the American Academy of Pain Medicine
(AAPM) (2012 to 2017), the European Pain Federation
(EFIC) (2012 to 2017), and the Multinational Associ-
ation for Supportive Care in Cancer (MASCC) (2012 to
2017), dependent on availability and (2) the trial registers
of the National Institute of Health (NIH) Register for
ongoing trials and the World Health Organization
(WHO) International Clinical Trials Registry Platform
(ICTRP).
All citations that will be identified in the database
searches will be imported in EndNote X8 (Clarivate An-
alytics, Philadelphia, PA, USA) after which duplicates
will be removed. For appraisal of the citations, we will
use exported Microsoft Excel files (Microsoft, Redmond,
WA, USA).
Study selection
We have developed an algorithm that will be followed in
the phase of evidence appraisal (see Fig. 1). The study
selection will consist of three phases.
Title selection
As we expect a large total number of citations, the first
round will consist of selection based on titles only. A re-
cent study that compared screening titles alone versus
titles and abstracts concluded that screening on title
alone may be more effective [18]. The entire selection
will be performed in duplicate by two independent re-
viewers (with extensive experience in both pediatric
Table 1 Overview of clinical questions and included outcomes per clinical question. Included outcomes differ per clinical question
and are highlighted with a number/color. The number represents the median score of the outcome in the guideline development
panel voting process. Outcomes with a score of 7–9 are considered critical to decision-making (highlighted green), outcomes with a
score of 4–6 are considered important, but not critical to decision-making (highlighted yellow), and outcomes with a score of 1–3
are considered of low importance to decision-making (none in this case)
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oncology and in systematic reviews, 1: EL, 2: WT). This
serves to exclude studies that are obviously irrelevant for
this review. A conservative approach to inclusion will be
employed to ensure relevant titles are not excluded. All
citations classified as “include” by at least one reviewer
will be included, even if the second reviewer classified
the citation as “exclude” (no discussion will be held). It
should be noted that this conservative approach is only
applied during the title selection phase. During abstract
and full-text selection, all discrepancies will be discussed
in detail and resolved by consensus.
To pilot the title selection process, two reviewers will
appraise the first 250 citations. If there is an agreement
below 85% percent, the title selection criteria will be opti-
mized and the pilot will be repeated on the next 250 cita-
tions. This continues until the agreement is at least 85%.
Abstract selection
The second round will consist of selection based on title
and abstract. The entire selection will be performed in
duplicate by two independent reviewers (1: EL, 2: di-
vided among JS, KB, MD, KK, MR, MW, and FG). A
pilot will be performed with the first 100 citations in a
similar fashion as with the title selection pilot. Hereafter,
discrepancies will be resolved by consensus, and if this is
not reached, a third reviewer will be consulted.
Full-text selection
In the final selection round, two independent reviewers
(the same as in the second round) will perform the se-
lection of the full texts. Discrepancies will be resolved by
consensus, and if this is not reached, a third reviewer
will be consulted.
Data extraction
Two reviewers will independently extract data from each
included study using a data abstraction form designed for
this systematic review (see Additional file 1). This form will
be pilot-tested by two reviewers with a representable sam-
ple of studies and, if necessary, optimized according to the
reviewers’ comments. The data extraction form differs
slightly for each clinical question, but includes at minimum
(1) general study information (i.e., first author, title, journal,
year, funding source), (2) study design characteristics (i.e.,
study design, setting, duration, sample size), (3) participant
characteristics (i.e., age, gender, diagnosis, age at diagnosis,
Table 2 Search strategy for PubMed/MEDLINE
# Search history Results
(March 22,
2017)
Explanation
#1 ((leukemia OR leukemi* OR leukaemi* OR (childhood ALL) OR AML OR lymphoma
OR lymphom* OR hodgkin OR hodgkin* OR T-cell OR B-cell OR non-hodgkin OR sar-
coma OR sarcom* OR sarcoma, Ewing’s OR Ewing* OR osteosarcoma OR osteosar-
com* OR wilms tumor OR wilms* OR nephroblastom* OR neuroblastoma OR
neuroblastom* OR rhabdomyosarcoma OR rhabdomyosarcom* OR teratoma OR
teratom* OR hepatoma OR hepatom* OR hepatoblastoma OR hepatoblastom* OR
PNET OR medulloblastoma OR medulloblastom* OR PNET* OR neuroectodermal tu-
mors, primitive OR retinoblastoma OR retinoblastom* OR meningioma OR menin-
giom* OR glioma OR gliom*) OR (pediatric oncology OR paediatric oncology) OR
(childhood cancer OR childhood tumor OR childhood tumors)) OR (brain tumor* OR
brain tumour* OR brain neoplasms OR central nervous system neoplasm OR central
nervous system neoplasms OR central nervous system tumor* OR central nervous
system tumour* OR brain cancer* OR brain neoplasm* OR intracranial neoplasm*)
OR (leukemia, lymphocytic, acute[mh]) OR (leukemia, lymphocytic, acute*)
1.641.231 Search filter for childhood cancer (from Cochrane Childhood
Cancer)
#2 Infan* OR toddler* OR minors OR minors* OR boy OR boys OR boyfriend OR
boyhood OR girl* OR kid OR kids OR child OR child* OR children* OR schoolchild*
OR schoolchild OR school child[tiab] OR school child*[tiab] OR adolescen* OR
juvenil* OR youth* OR teen* OR under*age* OR pubescen* OR pediatrics[mh] OR
pediatric* OR paediatric* OR peadiatric* OR school[tiab] OR school*[tiab]
4.334.396 Search filter for children (from Cochrane Childhood Cancer)
#3 pain[mh] OR acute pain[mh] OR chronic pain[mh] OR pain OR ache OR agony OR
hyperalgesia[mh] OR allodynia OR analgesia OR distress OR headache OR hurt[tiab]
OR hyperesthesia OR hyperaesthesia OR myalgia OR neuralgia OR neuropath* OR
polyneuropathy OR painful[tiab]
1.026.012 Search filter for pain (developed in consultation with the
information specialist from the Cochrane Childhood Cancer)
#4 Validation Studies[pt] OR “psychometrics”[MeSH] OR psychometr*[tiab] OR
clinimetr*[tw] OR clinometr*[tw] OR reproducibi*[tiab] OR reliabi*[tiab] OR
unreliabi*[tiab] OR validi*[tiab] OR valida*[tiab] OR “internal consistency”[tiab] OR
precision[tiab] OR imprecision[tiab] OR test–retest[tiab] OR repeatabi*[tiab] OR
((multitrait[tiab] AND scaling[tiab]) AND (analysis[tiab] OR analyses[tiab])) OR item
discriminant[tiab] OR sensitivi*[tiab] OR specifici* OR ((minimal[tiab] OR
minimally[tiab]) AND (clinical[tiab] OR clinically[tiab]) AND (important[tiab] OR
significant[tiab] OR detectable[tiab]) AND (change[tiab] OR difference[tiab])) OR
(small* AND (real[tiab] OR detectable[tiab]) AND (change[tiab] OR difference[tiab]))
OR pain measurement[mh]
2.068.426 Search filter measurement properties (developed in consultation
with the information specialist from the Cochrane Childhood
Cancer)
#5 #1 AND #2 AND #3 AND #4 1.804
#6 #5, filters: Humans; English 1.498
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type of pain), (4) measurement instrument characteristics
(i.e., instrument used, measurement method/dimensions),
(5) outcome characteristics (i.e., included outcomes, out-
come values), and (6) additional information (differs per
study, at the discretion of the reviewer). Reviewers will dis-
cuss the completed forms, and discrepancies will be re-
solved by consensus. If consensus is not reached, a third
reviewer will be consulted. In case of missing information,
the authors of the included study will be contacted in an ef-
fort to obtain this information.
Quality assessment
Two reviewers will independently assess the quality of the
included studies, according to the COSMIN checklist for
assessing methodological quality of studies on measure-
ment properties [15, 19]. This checklist is purpose-built
for the evaluation of measurement properties and takes a
three-tier approach. For multi-item measures, it is first de-
termined if the statistical methods are based on the clas-
sical test theory (CCT) or on the item response theory
(IRT); in the case of the latter, a separate quality checklist
Fig. 1 Flow diagram of the study selection process
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is included. Second, a checklist is completed for each
measurement property evaluated in each included paper
to evaluate if standards for good methodological quality
are met. Third and last, a checklist regarding the
generalizability of each outcome is completed. Discrepan-
cies between reviewers will be resolved in the same man-
ner as described for data extraction.
The COSMIN 4-point checklist scoring system will
result in a score per included outcome for each
study that can either be “excellent” (evidence that
the methodological quality is adequate), “good” (as-
sumed that the methodological quality is adequate,
but relevant information is not reported), “fair”
(doubtful whether the methodological quality is ad-
equate), or “poor” (evidence that the methodological
quality is not adequate). This serves the purpose of
identifying the measurement tool with the strongest
clinimetric properties.
Regarding publication bias, we will seek to identify
cues that imply this bias, e.g., identification of merely
studies that report measurement instruments with
strong clinimetric properties. A prospective registration
database, as there is for randomized controlled trials,
does not exist for measurement properties studies,
which makes identifying publication bias particularly
hard in this area of research. Also, there is no estab-
lished methodology for this, e.g., as there is for a
meta-analysis with a funnel plot. Therefore, we will com-
ment upon this in a qualitative manner.
Synthesis of results
Firstly, we will prepare a table of characteristics of in-
cluded studies where information regarding design, sam-
ple, measurement instrument(s), and outcome(s) will be
presented. Outcome tables will be prepared to cover each
measurement instrument (e.g., the Comfort Behavior
Scale) and each outcome construct (e.g., self-reported pain
intensity) separately. In addition, an outcome table will be
prepared which categorizes instruments according to age
group, i.e., 0–0.99 years (infants), 1–2.99 years (children
not able to speak or read), 3–6.99 years (children able to
speak, not able to read), 7–12.99 years (children able to
speak and read), and 12–18 years (teenagers). If the identi-
fied evidence leads to the conclusion that differently de-
fined age groups are more appropriate, we will reconsider
the definition of the age groups.
To provide a comprehensive overview, we will develop
a quality matrix. Herein, we will list all included meas-
urement instruments and the identified information on
purpose (self- or observer-report, type of pain), number
of studies, population/age group, and per outcome COS-
MIN quality score (four-level). This will allow the reader
to quickly identify the appropriate measurement instru-
ment with the strongest clinimetric properties.
In addition, we will present a narrative synthesis dis-
cussing our findings.
Discussion
In this protocol, we describe our approach for a system-
atic review regarding measurement properties of instru-
ments to assess pain and pain-related distress in
children and adolescents with cancer. This overview is
much needed for multiple reasons.
First, there is a clear difference between adults and
children. Second, besides this difference, there is also a
great difference between children across ages (e.g., a
15-year-old and a 3-year-old). Children go through vari-
ous developmental stages which lead to great variation
in this population in terms of abilities in verbal commu-
nication, pain experience, and associative thinking,
which will determine the appropriateness of individual
instruments within specific age groups [20]. Although
self-report is often regarded as the ideal method for
assessing pain, in young children, this is not always pos-
sible. Therefore, these populations have to rely on the
people around them (family members but also health-
care professionals) to notice and act upon their pain.
This underlines the importance of having clinimetrically
sound measurement instruments not just for self-report,
but also for proxy report. Third, children and adoles-
cents with cancer have various specific types of pain
which are often related to their disease (e.g., bone pain
due to metastases) or treatment (e.g., procedural pain,
vinca alkaloid-associated neuropathic pain). Fourth, pain
severity measurement is the critical first step to deter-
mine the need for treatment and to evaluate the success
of treatment. When pain is not measured, it is often
undertreated [21]. All of these reasons call for
age-specific measurement instruments with strong clini-
metric properties to assess pain in children and adoles-
cents with cancer.
Currently, there is great interest in reducing the
side-effects of cancer treatment in children and adoles-
cents, to reduce morbidity and improve quality of life.
Pain is frequently experienced by children and adoles-
cents with cancer and carries with it a great physical and
psychological burden [4]. It is known that not acknow-
ledging and treating pain can have a detrimental effect
on quality of life [22]. Therefore, it is of utmost import-
ance that healthcare professionals have access to the
available evidence and evidence-based recommendations
for care.
To address these needs, we have initiated a clinical
practice guideline development project that focuses on
formulating recommendations on the assessment and
treatment of pain in children and adolescents with can-
cer. This systematic review of the literature describing
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pain measurement instruments is the first step towards
formulating these recommendations.
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